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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.002AbstractThe Philadelphia chromosome (Ph+), corresponding to translocation t(9;22), is found in chronic
myeloid leukemia (CML) and acute lymphoblastic leukemia. Several cases of Ph+ acute myeloid leukemia
(AML) have been reported in the literature. A retrospective study of Ph+ AML between 2001 and 2012 was
conducted through a review of the literature. Among 400 AML patients, two cases of Ph+ AML (0.5%) were
identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs),
followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient had a complex
karyotype including 7 monosomy (7) and p190 BCR-ABL fusion transcript. Both patients remain in
complete molecular remission. To date, 21 Ph+ AML cases treated with TKIs have been described in the
literature with a median overall survival of 18 months. One-third of the patients had additional karyotypic
abnormalities, and 14% had 7. Molecular analysis showed 59% p210 and 41% p190 fusion protein.
Relapse rate was observed in 38% of patients with p190 compared to 10% in patients with p210. Allo-HSCT
was performed in eight patients; two relapsed (25%). Cytogenetic (7) and molecular features help to
distinguish Ph+ AML from CML. Survival improved with TKIs, particularly in association with conventional
chemotherapy and allo-HSCT. Further studies of Ph+ AML patients are needed to better define this entity, its
prognostic value, and therapeutic strategy.
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transplantationThe Philadelphia chromosome (Ph+) is theresult of a reciprocal translocation (t) involv-ing the long arms of chromosomes 9 and 22,
referred to as t(9;22)(q34;q11), producing a chimeric
gene that encodes the BCR-ABL fusion protein with
elevated tyrosine kinase activity. Depending on the
breakpoint of the ABL gene, the fusion protein has
different sizes, from the most frequently found p210
at 210 kD to the smallest, p190. The Philadelphia
chromosome is characteristic of but not restricted to
chronic myeloid leukemia (CML) and is frequently
present in acute lymphoblastic leukemia (ALL).1
The poor outcome of these hematopoietic malignan-cies appears to have improved since the introduction
of target therapy using tyrosine kinase inhibitors
(TKIs).2
The Philadelphia chromosome incidence in de
novo acute myeloid leukemia (Ph+ AML) is low at
approximately 0.5–3%.3 Ph+ AML is a controversial
entity and is not described in the 2008 revision of the
World Health Organization (WHO) classiﬁcation as
a separate entity.4 Its differential diagnosis is CML in
myeloid blastic crisis (CML-MBC) and mixed
phenotype acute leukemia with t(9;22)(q34;q11).
The criteria suggested for differentiating Ph+ AML
from CML-MBC include: no history of abnormalarter 2015
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hemograms, a lack of argument for a previous chronic
phase, and a lack of basophilia or splenomegaly.5
Cytogenetic and molecular features can be useful in
distinguishing this pathology.6 In CML-MBC, the
most common additional abnormalities are trisomy
8, trisomy 19 or isochromosome 17q, in addition to
t(9;22).5 Moreover, cooperation between mutations
suppressing cell differentiation (Core Binding Factor
AML) and mutations increasing cell proliferation
(e.g., the FLT3 gene, KIT gene) is more frequent in
Ph+ AML than in CML-MBC.7 Two recent studies
have shown that Nucleophosmin (NPM1) is com-
monly mutated in AML, whereas ABL1 mutations
are common in CML.4,8 More recently, Nacheva
et al. have shown a speciﬁc genome signature in de
novo Ph+ AML, which is distinctly different from
CML-MBC.7,9 Because of these distinctions between
Ph+ AML and CML-MBC, it is important to collect
new cases and research the cytogenetic, molecular or
genomic features to increase the argument in favor
of Ph+ AML as a real entity.
Here, two Ph+ AML cases are reported with a
review of the literature to determine the characteris-
tics, prognosis, and treatment of this rare entity.
MATERIALS AND METHODS
Patients
Newly diagnosed Ph+ AML patients reported
between 2001 and 2012 from the University Hospital
Center of Caen, in France.
Diagnostic criteria
Ph+ AML has been deﬁned as a de novo AML with a
t(9;22)(q34;q11) translocation in the bone marrow
karyotype, without argument for CML-MBC.10 Con-
ventional karyotyping was occasionally completed by
ﬂuorescence in situ hybridization (FISH) to determine
the BCR-ABL fusion gene transcript signal. Minimal
residual disease (MRD) was assessed by reverse tran-
scription-polymerase chain reaction (RT-PCR) and
detection of the BCR-ABL fusion gene transcript.
The BCR-ABL transcript level was then expressed as
a percentage, the BCR-ABL/ABL ratio, on the interna-
tional scale. This most sensitive technique was
performed on peripheral blood and bone marrow at
diagnosis and throughout the follow-up treatment. A
complete molecular response (CMR) was deﬁned by
the absence of RT-PCR-detected fusion transcript.4
RESULTS
During the study period, 400 patients were diagnosed
with AML at our institution. Four of them hadHematol Oncol Stem Cell Ther 8(1) First Quarter 2015t(9;22). Two of these patients were excluded from
the study: one most likely had CML-MBC with
splenomegaly and hemogram disturbance, and the
other had mixed-phenotype acute leukemia. The
crude incidence rate of Ph+ AML was 0.5%. These
two cases are reported in Table 1.
Case 1
A 42-year-old male presented with recurrent epistaxis
lasting for one month and a weeklong low-grade fever.
The hematologic parameters were as follows: hemo-
globin 70 g/L, platelets 20 g/L and white blood cells
(WBC) 0.8 g/L, with 14% blast cells. Bone marrow
aspiration showed blasts comprising 18% of all cells
and 36% of non-erythroid cells. The diagnosis of de
novo acute erythroid leukemia, according to WHO
classiﬁcation, was made. The cytogenetic analysis
(conventional karyotyping and FISH) showed ﬁve of
20 mitoses with t(9;22)(q34;q11), with a BCR-ABL
transcript level of approximately 10% and the p210
fusion protein. Molecular genetic analyses detected
the presence of NPM1 (nucleophosmin 1) gene
mutation.
The patient received induction therapy with
mitoxantrone, daunorubicin and cytosine arabinoside.
He achieved a complete cytogenetic response, with a
fusion transcript rate of 0.02%. Two courses of
high-dose cytosine arabinoside consolidation therapy
were performed, and the patient achieved CMR.
Seven months after diagnosis, he received matched
unrelated myeloablative allo-HSCT conditioned by
total body irradiation (TBI) and cyclophosphamide.
Eleven years after allo-HSCT, the patient remains
in continuous complete molecular remission, with
complete donor chimerism and no graft-versus-host
disease (GVHD).
Case 2
A 27-year-old female patient, 18 weeks pregnant,
reported abnormal weight loss since the beginning of
pregnancy. The complete blood count showed hyper-
leukocytosis at 30 g/L, with 54% blast cells. Bone mar-
row aspiration showed 63% myeloblasts, with 3%
positive for myeloperoxidase (MPO) coloration. The
diagnosis of de novo acute myeloid leukemia with min-
imal differentiation, according to WHO classiﬁcation,
was made. Karyotype analysis was complex, with three
clones: 46, XX, t(9;22)(q34;q11)(4)/46, idem, 7,
+mar(6)/45, idem, mar(7)/46, XX(2). ish7(D7Z1x3)
(8), 11q23(MLLx2)(3)nuc .ish(D7Z1x3)(69/200),
(MLLX2)(200). Molecular genetic analysis revealed
a p190 fusion protein and BCR-ABL fusion transcript
rate of 58%, without NPM1 mutation. Medical29
Table 1. Ph+ AML between 2001 and 2012 from University Hospital Center of Caen, France.
References Age
(year)/
sex
Karyotype BCR-
ABL
protein
NPM1
mutation
Chemotherapy Imatinib therapy Allo-
HSCT
Treatment
response
Survival
(months,
m)
InductionConsolidation InductionConsolidationMaintenance
Case 1 42/M 46,XY,t(9;22)(q34;q11) p210 Yes Yes Yes 0 0 0 Yes CR 135 m+
Case 2 27/F 46,XX,t(9;22)(q34;q11)(4)/46,idem, 7,+mar(6)/
45,idem,mar(7)/46,XX(2)
.ish7(D7Z1x3)(8),11q23(MLLx2)(3)nuc
ish(D7Z1x3)(69/200),(MLLX2)(200)
p190 No Yes Yes 0 600 mg/day 0 Yes CR 16 m+
M: male; F: female; Allo-SCT: allogeneic stem cell transplantation; CR: complete remission.
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case report CASE REPORTS ON PH+ AMLtermination of the pregnancy was performed. She
received induction therapy with daunorubicin, cyto-
sine arabinoside and imatinib mesylate (400 mg/day
from day 25 of the beginning of induction therapy).
She achieved a complete cytogenetic response, with a
BCR-ABL fusion transcript rate of 0.25%. Two
courses of high-dose cytosine arabinoside with imati-
nib (dose 600 mg/day) consolidation therapy were
performed. She received a matched, unrelated myelo-
ablative allo-HSCT conditioned by busulfan and
cyclophosphamide. One month after allo-HSCT, she
achieved a complete molecular response. At the time
of this report, sixteen months after allo-HSCT, she
remains in continuous CMR, with complete donor
chimerism and no GVHD.DISCUSSION
Only a few Ph+ AML cases treated with TKIs have
been reported in the literature. Among 36 cases of
Ph+ AML treated with TKIs, only 21 cases reported
sufﬁcient details for analysis (Table 2). The remaining
15 cases were eight cases of Ph+ AML treated with
imatinib and allo-HSCT,22 with a median survival
of 24 months (8–80), and seven cases of Ph+ AML
treated with imatinib alone.5 Ph+ AML cases
reported prior to the use of TKIs are not described
in our study. 6,23
Ph+ AML and CML-MBC are often clinically
similar, and a history of hemogram abnormalities is
often unknown. In 2013, two studies showed the
speciﬁcity of NPM1 mutation in AML and its
absence in CML.7,9 Unfortunately, we did not ﬁnd
molecular genetic research in the cases reviewed in
the literature (Table 2), but these studies suggest that
the presence of NPM1 mutation asserts Ph+ AMLand invalidates CML-MBC diagnosis. Additional kar-
yotyping might assist in the diagnosis of Ph+ AML,
and in our review it was effective in 38% of the cases
(eight of 21 patients: patients 4, 5, 11, 15, 18–21).
There were three cases of chromosome 7 monosomy
(7), two cases of chromosome 16 inversions, one
case each of short arm chromosome 5 deletion and
chromosome 10 deletion. If (7) is observed in 4%
of AML,11 this abnormality was present in our Case
2 and in three of the 21 cases reviewed (Table 2),
for a frequency of 14%.5,24,25 This abnormality
belongs to the AML frequent karyotype features,
and may help to distinguish Ph+ AML from CML-
MBC.5,6 Using microarrays, Nacheva et al. recently
showed that the unique loss within immunoglobulin
genes is a simple test enabling the differentiation of
clinically similar Ph+ AML and CML-MBC.10 This
last study proves the genomic distinction between
Ph+ AML and CML-MBC, but microarrays cannot
be used as a routine test; conversely, additional karyo-
type abnormalities and molecular features are always
identiﬁed yet can be useful for recognizing a Ph+
AML diagnosis. Such arguments for Ph+ AML case
reports should be used to recognize this rare but real
entity as a separate entity, which it currently is not in
the 2008 WHO classiﬁcation.
The p210 fusion protein is observed in 95% of
CML and in 20% of Ph+ ALL, in which the p190
fusion protein is more frequent. In contrast, authentic
de novo Ph+ AML expresses as much p210 fusion
protein as p190 fusion protein.1,26 Forty-one percent
of the patients reviewed (7/17) expressed the p190
BCR-ABL fusion transcript (Table 2). The prognostic
impact of the fusion protein size remains controver-
sial.26,27 Our review of Ph+ AML reveals a higher
rate of relapse in p190 AML (two of seven patients,Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
Table 2. Ph+ AML treated with tyrosine kinase inhibitors (TKIs) in the literature: diagnostic characteristics 46,XY,t(9;22)(q34;q11) alone or
46,XX,t(9;22)(q34;q11) alone = X BCR-ABL protein p210 = 2; BCR-ABL protein p190 = 1.
PatientsReferences Age (year)/
sex
Karyotype BCR-ABL
protein
1 12 46/M X 2
2 12 19/F X 2
3 13 67/M X 2
4 8 63/M 46,XY,inv(16)(p13;q22),t(9;22)(q34;q11) 1
5 8 64/F 46,XX,del(5q)(q14;q34),t(9;22)(q34;q11)/45,XX,del(5q)(q14;q34),
t(9;22)(q34;q11),dic(16;17)(q11;p11)
2
6 7 50/M X 2
7 7 48/F X 2
8 7 66/F X 1
9 7 49/F X 2
10 14 64/F X 2
11 15 52/F 46,XX,t(9;21;22)(q34;q21;q11)(17)/47,XX,t(9;21;22)(q34;q22;q11),+der(22)t(9;22)(q34;q11)(2) (at
relapse)
1
12 16 51/M No data 2
13 17 64/M X 1
14 18 73/M X 2
15 18 63/M 46,XY,der(9)t(9;22)(q34;q11), del(10)(q23), der(22)(9;10;22) 1
16 19 38/F X 1
17 20 53/F X 1
18 21 43/M 45,XY,7,t(9;22)(q34;q11) No data
19 21 44/M 45,XY,7,t(9;22)(q34;q11)(18)/46,XY(2) No data
20 21 25/M 46,XY,t(1;1;9;22)(p13;p36;q34;q11), inv(16)(p13;q22) No data
21 21 18/M 45,XY,t(9;22)(q34;q11)(18)/7,t(9;22)(q34;q11)(1)/ XY(1) No data
CASE REPORTS ON PH+ AML case report38%) compared to p210 AML patients (one of 10
patients, 10%) (Table 3).
The advent of TKI therapy, including imatinib,
has signiﬁcantly altered the treatment approach of
CML and reduced the frequency of allo-HSCT in
this pathology.28 Imatinib efﬁciency was proven in
blast crisis of CML (median survival of 6.9 months)29
and in patients with Ph+ ALL.2,30 TKIs have also
been used in Ph+ AML therapy (Table 3). Ph+
AML’s poor outcome (median survival without
TKI, nine months) seems to have improved since
the use of imatinib therapy.5 In our review, Ph+
AML showed a median survival of 18 months (range
6–71).Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015Imatinib resistance mechanisms are described in
this context, as they are in CML.31 Two of 21 patients
(9%, patients 5 and 17) were refractory to imatinib
therapy and received salvage therapy with dasatinib
(Table 3). As with CML-MBC, a deﬁnitive complete
response is unlikely to be achieved with only TKIs
because of the probability of BCR-ABL mutation.
Consequently, allo-HSCT appears to be the best con-
solidation therapy in Ph+ AML patients.32 Some
authors have shown that Ph+ AML patients must
be treated by TKIs and allo-HSCT if they are ﬁt
and have molecular or additional karyotype abnormal-
ities resulting in a poor outcome.12,21 Eight of 21
patients (38%) received allo-HSCT and TKIs, with31
Table 3. Ph+ AML treated with tyrosine kinase inhibitor (TKI) therapy in the literature: treatment and outcome (same patients as in Table 2).
PatientsReference Chemotherapy Imatinib therapy Allo-HSCT Treatment
response
Survival
(months, m)Induction Consolidation Induction Consolidation Maintenance
1 12 Yes Yes 0 400 mg/day 400 mg/day Yes CR 44 m
2 12 Yes Yes 0 300 mg/day 300 mg/day Yes CR 36 m+
3 13 No No 600 mg/day 600 mg/day 400 mg/day No CR 6 m+
4 8 Yes No Yes No No No relapse 10 m
5 8 No No 400 mg/day Dasatinib No Yes relapse 16 m
6 7 Yes Yes Yes Yes Yes No CR 71 m+
7 7 Yes Yes Yes Yes Yes No CR 36 m+
8 7 Yes Yes Yes Yes Yes No CR 32 m+
9 7 Yes Yes Yes Yes Yes No CR 28 m+
10 14 Yes No 0 600 mg/day 600 mg/day No CR 15 m+
11 15 Yes before
relapse
Yes before
relapse
600 mg/day at
relapse
600 mg/day 600 mg/day No CR2 48 m+
12 16 Yes No 0 600 mg/day 400 mg/day No CR No data
13 17 Yes No 600 mg/day 400 mg/day 300 mg/day No CR 18 m+
14 18 Yes No 0 600 mg/day 400 mg/day No CR 19 m+
15 18 Yes No 0 400 mg/day 400 mg/day No CR 12 m+
16 19 Yes No 0 600 mg/day 600 mg/day No CR 10 m+
17 20 Yes Yes 400 mg/day 400 mg/day Dasatinib for relapse after allo-
HSCT (+ 6 to 12 m)
Yes relapse
after 6 m
CR2 18 m+
18 21 Yes Yes 0 400 mg/day 0 Yes CR 25 m+
19 21 Yes Yes 0 400 mg/day 0 Yes CR 9 m+
20 21 Yes Yes 0 400 mg/day 0 Yes CR 6 m+
21 21 Yes Yes 0 400 mg/day 0 Yes CR 6 m+
32
case report CASE REPORTS ON PH+ AMLa median survival of 17 months (range 6–44)
(Table 3). Among them, two had relapsed. The ﬁrst
(patient 5 in Tables 2 and 3), with a complex karyo-
type, was not treated with conventional induction che-
motherapy, and he died without salvage therapy. The
second patient (patient 17 in Tables 2 and 3), with
p190 fusion protein, relapsed at six months after
allo-HSCT and received a second-generation TKI as
salvage therapy; one year later, he remains in continu-
ous CR. Thirteen unﬁt patients (59%), ineligible for
allo-HSCT, were treated with a TKI (imatinib) as
long-term maintenance therapy, similar to the CML
patients’ treatment, with a median survival of
18.5 months (range 6–71) (Table 3). Twelve of them
(92%) achieved complete CR.CONCLUSION
Ph+ AML cases, despite scarce data found in the lit-
erature, have to be considered as de novo AML. The
patients’ clinical features (no history of abnormal
hemograms, lack of an argument for a previous
chronic phase and lack of basophilia or splenomegaly),
cytogenetic abnormalities (chromosome 7 monosomy,
chromosome 16 inversions and chromosome 10 dele-
tions), molecular features (NPM1 mutation and p190
prevalence) and genome signature are different from
those with CML. The Ph chromosome allowed the
use of target therapy (TKI) in association with con-
ventional chemotherapy. Future epidemiological stud-
ies of Ph+ AML patients have to be performed, as inHematol Oncol Stem Cell Ther 8(1) First Quarter 2015
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this report, to ensure the recognition of this disease as
a distinct entity. A large-scale registry could contrib-
ute to a better therapeutic strategy.CONFLICT OF INTEREST
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